Dr. Daniel E. Okobi JR., M.D., PH.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 157
Licensed in California since 2019, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: New York University School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME162637 · CA license A162136 (first issued 2019; current) · WI license 82141
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Orlando Health Orlando, FL
- Adventhealth Waterman Tavares, FL
- Adventhealth Fish Memorial Orange City, FL
- Adventhealth Heart of Florida Davenport, FL
Medical groups
- Florida Hospital Medical Group Inc (1,755 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 157
- Services billed
- 310
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 26 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Orlando, FL | 254 |
| Memantine Hcl Other prescribers in Orlando, FL | 117 |
| Galantamine Er (galantamine hbr) Other prescribers in Orlando, FL | 62 |
| Escitalopram Oxalate Other prescribers in Orlando, FL | 33 |
| Rivastigmine Other prescribers in Orlando, FL | 33 |
| Rivastigmine (rivastigmine tartrate) Other prescribers in Orlando, FL | 29 |
| Atorvastatin Calcium Other prescribers in Orlando, FL | 27 |
| Quetiapine Fumarate Other prescribers in Orlando, FL | 25 |
| Mirtazapine Other prescribers in Orlando, FL | 18 |
| Rosuvastatin Calcium Other prescribers in Orlando, FL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $303 in total to this clinician.
| Eisai Inc. | $112 |
|---|---|
| Teva Pharmaceuticals USA, Inc. | $101 |
| Novo Nordisk Inc | $90.33 |
| Food and Beverage | $303 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $806,320 in research payments for these studies, mostly to the institutions running them.
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.